Japan’s market growth accelerates through dynamic clinical partnerships, biologic breakthroughs, and automated facilities.

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

A new European survey sponsored by AstraZeneca (AZ) and Daiichi Sankyo has revealed widespread misconceptions about breast ...

Jefferies analyst Stephen Barker maintained a Hold rating on Astellas Pharma (ALPMF – Research Report) yesterday and set a price target of ...

Jefferies analyst Stephen Barker maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on January 19 and set a price ...

The addition of anthracyclines to adjuvant taxane-based chemotherapy improved survival for certain high-risk patients with ...

Daiichi Sankyo establishes “Smart” Research Laboratory in San Diego to expedite drug discovery: Tokyo Thursday, January 23, 2025, 13:00 Hrs [IST] Daiichi Sankyo, an innovative ...

As global markets witness a rebound driven by easing core inflation in the U.S. and strong bank earnings, major indices such as the S&P 500 and Nasdaq Composite have recorded significant gains, ...

Risk for bleeding events is significantly affected by DOAC score in patients with atrial fibrillation who have received TAVR.

Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA ...

The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the ...